Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
Regul Toxicol Pharmacol
; 98: 98-107, 2018 Oct.
Article
em En
| MEDLINE
| ID: mdl-30026135
Palavras-chave
Adversity; Biopharmaceuticals; Bispecifics; Cytokine release; Emerging therapies; Gene and cell therapies; Gene editing; Immune-oncology; Immunomodulation; Microbiome; Minimum anticipated biological effect level (MABEL); Monoclonal antibodies; No observed adverse effect level (NOAEL); Nonclinical safety; Nonclinical species selection; Oligonucleotide; Orphan drug; Pharmacodynamics (PD); Pharmacokinetics (PK); Recombinant proteins
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Produtos Biológicos
/
Avaliação Pré-Clínica de Medicamentos
Tipo de estudo:
Etiology_studies
/
Guideline
/
Qualitative_research
/
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article